Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Dose reduction of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: A Danish nationwide cohort study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Candidate single nucleotide polymorphisms and thromboembolism in acute lymphoblastic leukemia - A NOPHO ALL2008 study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Role of spleen and liver for enhanced hemostatic competence following administration of adrenaline to humans

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Managing antiphospholipid syndrome in pregnancy

    Research output: Contribution to journalReviewResearchpeer-review

  4. Venous thromboembolism in epithelial ovarian cancer. A prospective cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Prevalence and significance of anti-phosphatidylserine antibodies: A pooled analysis in 5992 patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Cardiovascular complications in patients with total cavopulmonary connection: A nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Favorable five-year outcomes for heart failure diagnosed in younger patients without severe comorbidity

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Quality of life and the associated risk of all-cause mortality in nonischemic heart failure

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. One-year outcomes in atrial fibrillation presenting during infections: a nationwide registry-based study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

INTRODUCTION: To investigate the patterns of dose reduction of non-vitamin K antagonist oral anticoagulants (NOAC) in patients with atrial fibrillation (AF).

MATERIALS AND METHODS: Using Danish nationwide registries, we identified all non-valvular AF patients initiated on standard-dose NOAC during 2011-2017 who were followed until dose reduction. The absolute risk of dose reduction was presented as cumulative incidence both overall and according to baseline characteristics. Moreover, to assess baseline comorbidities related to dose reduction, adjusted Cox regression models were used. In subgroup analysis, we investigated dose reduction following acute myocardial infarction and/or percutaneous coronary intervention (MI/PCI), chronic kidney disease (CKD), turned 80 years, intracranial hemorrhage, peripheral bleeding, ischemic stroke, cancer, bone fracture, and antiplatelet treatment start.

RESULTS: Of 24,489 patients included, 12.2% experienced dose reduction during the study period. Dabigatran treatment, higher age at inclusion, high CHA2DS2-VASc score, and high HAS-BLED score were related to higher risk of dose reduction. Baseline ischemic heart disease (IHD), heart failure, cancer, CKD, chronic obstructive pulmonale disease (COPD), and hypertension were independent predictors of dose reduction. In subgroup analysis with six-month follow-up, MI/PCI, CKD, intracranial hemorrhage, peripheral bleeding, and antiplatelet treatment therapy were strongly associated with dose reduction.

CONCLUSIONS: Dose reduction of NOACs was observed in 12.2% of AF patients during 2011-2017 and was associated with dabigatran treatment, advanced age at baseline, high CHA2DS2-VASc score, and high HAS-BLED score. Among comorbidities, IHD, heart failure, cancer, CKD, COPD, and hypertension predicted dose reduction independently. During six-month follow-up, MI/PCI showed the strongest association with dose reduction.

Original languageEnglish
JournalThrombosis Research
Volume178
Pages (from-to)101-109
Number of pages9
ISSN0049-3848
DOIs
Publication statusPublished - 1 Jun 2019

    Research areas

  • Apixaban, Atrial fibrillation, Dabigatran, Dose reduction, NOAC, Rivaroxaban

ID: 58043183